NASDAQ$SKIN
SkinHealth Systems Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported double-digit net sales growth and raised fiscal 2023 net sales guidance due to strong consumer demand.
BeautyHealth reported a 14% increase in net sales to $86.3 million, driven by strong consumer demand for Hydrafacial treatments. The company raised its fiscal year 2023 net sales guidance to $460 - $480 million and reaffirmed its adjusted EBITDA margin guidance of 18% - 20%.
- Net sales increased by 14% year-over-year, reaching $86.3 million.
- Consumables net sales grew by 21% year-over-year globally, with significant growth in the Americas (+34%) and EMEA (+13%).
- Delivery system sales increased by 9% year-over-year.
- The company raised its fiscal year 2023 net sales guidance to $460 - $480 million.
Headline financials
Revenue & EPS history
Beauty Health · Revenue · Quarterly
$86.3M
Revenue by segment
Beauty Health · $86.3M total across 2 segments · Q1 2023
- Delivery Systems$45.4M+9.1%52.6%
- Consumables$40.9M+21.0%47.4%
Forward guidance
The company raised its fiscal year 2023 net sales guidance to a range of $460 to $480 million due to continued strength in consumer demand, strong Syndeo traction globally, and a re-acceleration in China. The adjusted EBITDA margin is expected to be 18%-20%.
Tailwinds
- Continued strength in consumer demand
- Strong Syndeo traction globally
- Re-acceleration in China
- No material deterioration in general market conditions or other unforeseen circumstances beyond our control.
- Assumes a largely re-opened global market
Headwinds
- Assumes no material deterioration in general market conditions or other unforeseen circumstances beyond our control.
- Excludes any unannounced acquisitions, dispositions or financings during 2023.
- Assumes a largely re-opened global market, which would be negatively impacted if closures related to COVID-19 or other restrictive measures are reimplemented.
- Assumes no material deterioration in foreign currency exchange rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+0.6%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-1.9%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+52.1%
Q1 2025
Best reaction
-61.4%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | -29.9% | -34.9% | |
| Q4 2025 | +19.8% | +11.3% | -15.3% | |
| Q3 2025 | +8.7% | +3.1% | +13.2% | |
| Q1 2025 | +52.1% | +19.4% | +29.0% | |
| Q4 2024 | -5.6% | -9.9% | -26.1% | |
| Q3 2024 | +5.1% | -13.1% | -14.2% | |
| Q2 2024 | -10.4% | +0.8% | +12.8% | |
| Q1 2024 | -20.1% | -18.4% | -39.9% | |
| Q4 2023 | +16.8% | -0.8% | +4.4% | |
| Q3 2023 | -61.4% | -37.2% | -14.7% | |
| Q2 2023 | -6.0% | -12.9% | -24.2% | |
| Q1 2023 | -2.8% | -0.2% | -20.8% | |
| Q4 2022 | +8.7% | +13.5% | +7.4% | |
| Q3 2022 | -25.3% | -12.3% | -4.1% | |
| Q2 2022 | -8.3% | -8.8% | -18.5% | |
| Q1 2022 | -5.4% | +6.6% | +8.9% | |
| Q4 2019 | +4.0% | -4.1% | -12.9% | |
| Q4 2021 | +23.4% | +43.1% | +27.6% | |
| Q3 2021 | -11.9% | -8.0% | -13.9% | |
| Q2 2020 | +8.2% | +7.4% | +26.8% | |
| Q2 2021 | +10.6% | +23.9% | +30.3% | |
| Q1 2021 | +12.8% | +15.9% | +44.7% | |
| Q4 2020 | +2.8% | -0.9% | -10.0% | |
| Q3 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro